Variations in the Frequencies of Polymorphisms in the CYP450s Genes in Eight Major Ethnicities of Iran: A Review of the Human Data

Navid Neyshaburinezhad 1, Hengameh Ghasim 1, Mohammadreza Rouini 1, Youssef Daali 2,3,* and Yalda H. Ardakani 1,*

1 Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 14176-14411, Iran
2 Division of Clinical Pharmacology and Toxicology, Geneva University Hospitals, 1205 Geneva, Switzerland
3 Faculty of Medicine, University of Geneva, 1206 Geneva, Switzerland
* Correspondence: youssef.daali@unige.ch (Y.D.); yh-ardakani@tums.ac.ir (Y.H.A.)

Abstract: Genetic polymorphisms in cytochrome P450 genes can cause variation in metabolism. Thus, single nucleotide variants significantly impact drug pharmacokinetics, toxicity factors, and efficacy and safety of medicines. The distribution of CYP450 alleles varies drastically across ethnicities, with significant implications for personalized medicine and the healthcare system. We combined whole-genome and exome sequencing data to provide a review of CYP450 allele polymorphisms with clinical importance. Data were collected from 800 unrelated Iranians (100 subjects from 8 major ethnicities of Iran), more than 32,000 unrelated Europeans (other than Caucasian), and four Middle Eastern countries. We analyzed the frequencies and similarities of 17 CYP450 frequent alleles related to nine important CYP450 isoenzymes and homozygous and heterozygous genotypes based on these alleles in eight major Iranian ethnics by integrating these data with population-specific linkage information and compared these datasets with mentioned populations.

Keywords: Iranian ethnicities; CYP450 genotype; polymorphism; SNP

1. Introduction

Personalized medicine is one of the highly advanced fields of medical sciences. This branch of science delves into the patient’s physiologic and pathophysiologic features and selects and carries out an appropriate and specific therapeutic approach for the patient [1]. Concentrating on the patient as the focal point rather than the disease augments the treatment effectiveness and decreases the probable side effects [2]. Despite the positive aspects of this system, achieving such an extent of knowledge of the patient’s features to implement personalized medicine necessitates a tremendous amount of detailed information about patient physiology and pathophysiology [3,4]. The genetic assessment and the specific genes of each individual are two of the most significant characteristics that help us achieve this level of knowledge of the patient’s features [5]. So far, there have been numerous studies regarding the matter at hand. Primarily, an effort has been made to genetically assess the specific populations, such as the people of a country, and compare them to other countries [6–8]. Following that, the ethnicities of various countries have been studied and compared [9–11]. Such assessments/studies greatly help access the required information and individualized therapies. It also improves our understanding of the population’s genetic characteristics and the similarities and differences between individuals. The final stage of personalized medicine is thoroughly understanding each individual and identifying the physiologic and pathophysiologic similarities and disparities between patients [12]. It should be noted, however, that genetic assessment alone is insufficient to realize personalized medicine fully; phenotypic assessment is also crucial.
Numerous studies have demonstrated that a patient’s response to a therapeutic approach or a prescribed pharmaceutical is not commensurate with his or her genetic profile [13–15].

Cytochrome p450 (CYP450) is one of the most potent metabolizing enzymes in the body. It metabolizes many endogenic and exogenic substances [16–18]. Differences in genotype and phenotype alter the enzyme’s activity. Aside from intra-individual changes in these enzymes’ activity by several physiological, pathological, and environmental factors [19–25], any change in the enzyme activity may alter pharmacotherapeutic efficiency and decrease or increase adverse drug reactions [26–29]. Hence, in personalized medicine, the enzyme family is one of the parameters that increase the specificity of pharmacotherapy in patients under investigation. A genetic assessment of CYP450 enzymes reveals that they fall into four categories: poor, intermediate, extensive, and ultra-rapid metabolizers, which have low, moderate, usual, and high activity, respectively [30]. As previously stated, the patient’s response to therapy is not always consistent with his genotype. For instance, the patient’s genotype indicates that the CYP450 enzyme is normal, but the pharmacotherapy response indicates the enzyme’s decreased activity [31]. In such cases, it has been demonstrated that an enzyme’s activity and phenotype are not concordant with the corresponding genotype for various reasons, such as diseases, medication use, diet, and the like. This phenomenon is known as phenocoversion. Nonetheless, the primary assessment of personalized medicine begins with genotyping [32,33].

In recent years, several studies have been conducted on the genotype of some cytochrome 450 enzymes in the Iranian population. In these studies, one cytochrome was investigated in one group of patients or a specific ethnicity [11,34–36]. However, no study has comprehensively investigated the important cytochromes P450 across various ethnicities in Iran’s population. In a review study, our research team studied the most critical enzymes of the cytochrome P450 family in the Iranian population and compared the results to those of the world’s five most significant populations (Europeans, Americans, Latinos, eastern and middle east Asia, and the Caucasian ethnicity). Results revealed that, while there are some similarities, there are many genotype differences between the cytochrome P450 enzyme of the Iranian population and the other populations mentioned above [37]. These findings highlighted the importance of conducting additional individual studies on the Iranian population to gain more information. Such data can advance personalized medicine, improve pharmacotherapy efficiency, and reduce probable unintended adverse effects in Iranian patients (concerning the genetic profile of cytochrome P450 enzymes).

For this reason, in this review article, our team investigated the genotype profile of the most critical cytochrome P450 enzymes in Iran across various ethnicities. Approximately 90 percent of drugs are metabolized through these enzymes. These enzymes include CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. According to the study results, Iran’s population is divided into eight ethnicities of Arab, Azeri, Baloch, Kurd, Lur, Persian, Persian Gulf Islander, and Turkmen. Each group consisted of 100 healthy people who were studied. The required information was extracted, classified, and analyzed from the Iranome database, other available human genome variation databases, and a literature review. To our knowledge, the resulting data provide an immense overview of CYP450 allele distributions in Iranian ethnicities. They provide essential information for guiding ethnic-specific genotyping strategies in pharmacokinetic studies and, eventually, in personalized medicine.

2. Methods

2.1. Allele Frequency Data

The frequency of 17 alleles of eight cytochromes (CYP3A4 without SNP with a frequency above 0.5% among the Iranian population) was investigated in the current study using data from 8 main Iranian ethnicities (800 subjects) on the Iranome website. Furthermore, the frequency of these alleles among Iranian ethnicities was compared to the European population (32,299 Genomes) using the website [https://gnomad.broadinstitute.org, accessed on 10 August 2022]. It also was compared to the Caucasian race and four Middle
Eastern countries’ (Egypt, Saudi Arabia, Turkey, and United Arab Emirates) populations through the related papers (50–250 people reported in each paper) (Table 1).

Table 1. Number of Genomes sequenced in 8 Iranian Ethnicities compared to the European population and Caucasian race.

| Population | Ethnicities | Description | Genomes |
|------------|------------|-------------|---------|
| IRN        | Arab       | Iranian (Based on [https://Iranome.ir, accessed on 10 August 2022]) | 100     |
| IRN        | Azeri      | Iranian (Based on [https://Iranome.ir, accessed on 10 August 2022]) | 100     |
| IRN        | Baloch     | Persian Gulf Islander | 100     |
| IRN        | Kurid      | Persian Gulf Islander | 100     |
| IRN        | Lur        | Persian Gulf Islander | 100     |
| IRN        | Persian    | Persian Gulf Islander | 100     |
| IRN        | Turkmen    | Persian Gulf Islander | 100     |

European

- Non-Finnish European (Based on [https://gnomad.broadinstitute.org, accessed on 10 August 2022]) | ~32,000 |

Middle Eastern

- Middle eastern (Based on a literature review [38–52]) | ~50–200 |

Caucasian

- Caucasian (Based on a literature review [6,7,10,14,37,53–55]) | ~100–250 |

2.2. Allele Nomenclature and Definitions

CYP star (*) alleles were defined according to the Human CYP Allele Nomenclature Database (http://www.pharmvar.org, accessed on 10 August 2022) and (http://www.SNPedia.com, accessed on 10 August 2022). Tables 2–4 compare high-frequency alleles (SNPs) among major Iranian ethnicities and other populations (European, Middle Eastern) and Caucasian races. Tables 5 and 6 show the frequency of CYP450s homozygous and heterozygous genotypes based on the most frequent SNPs in major ethnicities and the Iranian population (mean). Differences of less than 1% were considered similar. Lastly, the rate of homozygote and heterozygote genotypes of these alleles in Iranian ethnicities was compared.

Table 2. Prevalence of frequent alleles associated with nine CYP450 genes in major Iranian ethnicities.

| Allele     | Arab  | Azeri | Baloch | Kurd  | Lur  | Persian | PG1* | Turkmen |
|------------|-------|-------|--------|-------|------|---------|------|---------|
| CYP1A2*1F  | 61.8  | 58.7  | 55.5   | 65.9  | 62.8 | 66.8    | 50   | 57.4    |
| CYP2B6*9   | 27.6  | 27    | 26     | 26    | 30.5 | 24      | 26   | 25.7    |
| CYP2B6*5   | 10    | 8.5   | 10     | 8.5   | 8.5  | 6.5     | 7    | 9       |
| CYP2B6*2   | 6.6   | 4     | 6      | 7.5   | 6    | 8.5     | 2.5  | 1.5     |
| CYP2B6*22  | 3     | 2.5   | 3      | 2     | 2    | 4.5     | 1    | 3       |
| CYP2B6*3   | 1.5   | 1     | 0      | 1.5   | 1.5  | 4       | 0.5  | 0.5     |
| CYP2B6*4   | 2.5   | 4     | 0.5    | 5.5   | 2.5  | 3.5     | 0.5  | 2.5     |
| CYP2B6*22  | 2.5   | 1.5   | 4.5    | 1.5   | 1    | 2       | 6    | 0       |
| CYP2B6*2   | 7     | 11.6  | 8      | 8.5   | 15   | 14.5    | 9.5  | 10      |
| CYP2B6*3   | 7     | 7.5   | 14.5   | 9     | 10   | 9.5     | 13.5 | 11      |
| CYP2B9*2   | 12.6  | 11    | 18     | 11    | 11   | 15.5    | 11   | 15.5    |
| CYP2B6*2   | 48    | 42    | 53     | 48.5  | 46.4 | 44.5    | 51.5 | 42.5    |
| CYP2B6*10  | 10    | 22.5  | 12.5   | 15.5  | 15   | 13.5    | 14.5 | 17.5    |
| CYP2B6*41  | 15.5  | 16    | 14     | 14.5  | 15.6 | 18.5    | 8.6  | 9.5     |
| CYP2B6*4   | 7.5   | 17    | 11.5   | 9.5   | 11.5 | 12      | 12   | 9       |
| CYP2B6*2   | 4     | 3.5   | 5      | 7.5   | 5.5  | 8       | 6.5  | 5       |
| CYP3A4     | 94.8  | 95.5  | 95.5   | 95.4  | 96.3 | 98.2    | 95.9 | 97.7    |
| CYP3A5*3   | 94.8  | 95.5  | 95.5   | 95.4  | 96.3 | 98.2    | 95.9 | 97.7    |

* Persian Gulf Islander.
Table 3. The similarity of high-frequency alleles (SNPs) in major Iranian ethnicities with the Caucasian race and European population.

| CYP450 | Allele | IRN Ethnics Similar to Caucasian | Caucasian | IRN Ethnics Similar to European | European |
|--------|--------|---------------------------------|-----------|---------------------------------|----------|
| CYP1A2 | *1F (rs762551) | None | 73.7% [55] | None | 69.9% |
| CYP2B6 | *9 (rs3745274) | Arab (27.6%)-Baloch (10%) | 28.6% | Persian (24%) | 24% |
|       | *5 (rs3211371) | Arab (10%)-Baloch (10%) | 10.9% | None | 11.8% |
|       | *2 (rs8192709) | Baloch (6%)-Lur (6%) | 5.3% | Arab (6.6%)-Baloch (6%)-Lur (6%) | 5.6% |
|       | *22 (rs34423104) | Arab (3%)-Baloch (3%)-Turkmen (3%)-Azeri (2.5%)-Kurd (2%)-Lur (2%) | 2.4% | Kurd (2%)-Lur (2%)-Persian Gulf Islander (1%) | 1.1% |
|       | *3 (rs45482602) | Azeri (1%)-Persian Gulf Islander (0.5%)-Turkmen (0.5%) | <1% | Azeri (1%)-Persian Gulf Islander (0.5%)-Turkmen (0.5%) | <1% |
| CYP2C8 | *4 (rs1058930) | None | 5.5% | Kurd (5.5%) | 5.4% |
|       | *2 (rs11572103) | Lur (1%) | <1% | Lur (1%) | <1% |
| CYP2C9 | *2 (rs1799853) | None | 13.3% | Azeri (11.6%) | 12.6% |
| CYP2C19 | *3 (rs1057910) | None | 5.6% | Arab (7%)-Azeri (7.5%) | 6.8% |
|        | *2 (rs4244285) | Arab (12.6%) | 13.6% | Persian (15.5%)-Turkmen (15.5%) | 14.6% |
| CYP2D6 | *2 (rs16947, rs1135840) | All ethnics (42-53%) | 32.8-82.5% | None | 34.3% |
|        | *10 (rs1065852, rs1135840) | None | 19.6% | None | <1% |
|       | *41 (rs28371275) | Turkmen (9.5%)-Persian Gulf Islander (8.6%) | 9.6% | Turkmen (9.5%) | 9.3% |
|        | *4 (rs3892097) | None | 18.2% | None | 19.6% |
| CYP2E1 | *4 (rs6413419) | NA | - | None | 2.2% |
| CYP3A5 | *3 (rs776746) | Baloch (95.5%)-Kurd (95.4%)-Persian Gulf Islander (95.9%)-Azeri (95%)-Arab (94.8%) | 95.5% | None | 93% |

Table 4. The similarity of high-frequency alleles (SNPs) in major Iranian ethnicities with 4 Middle East countries.

| CYP450 | Allele | IRN Ethnics Similar to Middle Eastern | Turkish Pop. | Saudi Arabia Pop. | Egyptian Pop. | Emirati Pop. |
|--------|--------|---------------------------------------|--------------|------------------|---------------|--------------|
| CYP1A2 | *1F (rs762551) | None | 27% | - | 68% | - |
| CYP2B6 | *9 (rs3745274) | Lur (30.5) | 11% | - | 28.8% | 30% |
|       | *5 (rs3211371) | None | 2% | - | 3.8% | - |
|       | *2 (rs8192709) | - | - | - | - | - |
|       | *22 (rs34423104) | - | - | - | - | - |
|       | *3 (rs45482602) | - | - | - | - | - |
| CYP2C8 | *4 (rs1058930) | Arab (2.5%)-Lur (2.5%)-Turkmen (2.5%) | 2.3% | - | - | - |
|       | *2 (rs11572103) | - | - | - | - | - |
| CYP2C9 | *2 (rs1799853) | Azeri (11.6%)-Turkmen (10%) | 10.6% | 13.3% | 12% | 11% |
|       | *3 (rs1057910) | Arab (7%)-Azeri (7.5%)-Kurd (9%)-Lur (10%)-Persian (9.5%)-Turkmen (11%) | 10% | 2.3% | 6% | 7% |
Table 4. Cont.

| CYP450 | Allele | IRN Ethnics Similar to Middle Eastern | Turkish Pop. | Saudi Arabia Pop. | Egyptian Pop. | Emirati Pop. |
|--------|--------|---------------------------------------|--------------|-------------------|---------------|--------------|
| CYP2C19 | *2 (rs4244285) | Baloch (18%)-Persian (15%)-Turkmen (15%) | 18.3% | 15% | 3.8% | 15% |
|        | *2 (rs16947, rs1135840) | None | 35% | 10.4% | 31.3% | 12.2% |
|        | *10 (rs1065852, rs1135840) | None | 26% | 3% | 3.4% | 3.3% |
| CYP2D6 | *2 (rs16947, rs1135840) | Arab (15.5%)-Azeri (16%)-Baloch (14%) | 15% | 18.4% | 15.1% | 15.2% |
|        | *10 (rs1065852, rs1135840) | Arab (15.5%)-Azeri (16%)-Baloch (14%)-Kurd (14.5%)-Lur (15.6%)-Persian (18.5%) | 1% | 3.5% | 18.1% | 9% |
| CYP2E1 | *4 (rs3892097) | Arab (15.5%)-Azeri (16%)-Baloch (14%)-Kurd (9.5%)-Turkmen (9%) | 15% | 3% | 18.4% | 2% |
| CYP3A5 | *3 (rs776746) | None | 3% | 3% | 14% | 14% |

Table 5. The frequency of CYP450s homozygous and heterozygous genotypes based on the most frequent SNPs in major Iranian ethnicities.

| Ethnic | 1A*2| 1B*6| 1B*9| 1B*2| 1B*5| 1B*9| 1B*2| 1C8*2| 1C8*4| 1C9*2| 1C9*3| 1C9*2| 1D6*2| 1D6*4| 1D6*10| 1D6*41| 1E1*4| 1A5*3 |
|--------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arab   | 45.3% | 1.0% | 0.0% | 1.0% | 7.0% | 0.0% | 0.0% | 0.0% | 1.0% | 0.0% | 1.0% | 0.0% | 24.0% | 1.0% | 1.0% | 1.0% | 0.0% | 88.0% |
| Azeri  | 38.1% | 0.0% | 0.0% | 1.0% | 7.0% | 0.0% | 0.0% | 1.0% | 1.0% | 0.0% | 0.0% | 2.0% | 17.0% | 4.0% | 7.0% | 4.0% | 0.0% | 90.0% |
| Baloch | 34.3% | 1.0% | 0.0% | 2.0% | 6.0% | 0.0% | 1.0% | 0.0% | 0.0% | 0.0% | 5.0% | 4.0% | 32.0% | 3.0% | 4.0% | 4.0% | 0.0% | 93.9% |
| Kurd   | 51.5% | 1.0% | 0.0% | 1.0% | 5.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | 2.0% | 26.0% | 1.0% | 3.0% | 4.0% | 1.0% | 92.0% |
| Lur    | 45.3% | 0.0% | 0.0% | 0.0% | 9.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 1.0% | 27.2% | 0.0% | 1.0% | 4.0% | 1.0% | 96.0% |
| Persian| 47.3% | 1.0% | 0.0% | 0.0% | 5.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.0% | 4.0% | 21.0% | 1.0% | 2.0% | 3.0% | 0.0% | 99.0% |
| PGI*   | 31.6% | 0.0% | 0.0% | 0.0% | 5.0% | 0.0% | 0.0% | 1.0% | 2.0% | 3.0% | 3.0% | 29.0% | 1.0% | 1.0% | 3.0% | 0.0% | 95.0% |
| Turkmen| 39.0% | 0.0% | 0.0% | 0.0% | 6.1% | 0.0% | 0.0% | 0.0% | 0.0% | 1.0% | 2.0% | 19.0% | 3.0% | 6.0% | 2.0% | 0.0% | 97.0% |
| Turkmen| 32.9% | 11.0% | 3.0% | 18.0% | 41.0% | 6.0% | 5.0% | 5.0% | 12.0% | 14.0% | 23.0% | 48.0% | 13.0% | 18.0% | 15.0% | 8.0% | 11.0% |
| Azeri  | 41.2% | 8.0% | 2.0% | 15.0% | 40.0% | 6.0% | 3.0% | 6.0% | 21.0% | 15.0% | 18.0% | 50.0% | 26.0% | 31.0% | 29.0% | 7.0% | 9.0% |
| Baloch | 42.4% | 10.0% | 0.0% | 16.0% | 40.0% | 6.0% | 7.0% | 1.0% | 16.0% | 19.0% | 28.0% | 42.0% | 17.0% | 17.0% | 11.0% | 10.0% | 6.1% |
| Kurd   | 28.8% | 13.0% | 3.0% | 15.0% | 42.0% | 4.0% | 3.0% | 11.0% | 17.0% | 14.0% | 18.0% | 45.0% | 17.0% | 25.0% | 23.2% | 13.0% | 8.0% |
| Lur    | 35.0% | 12.0% | 3.0% | 17.0% | 43.0% | 4.0% | 2.0% | 5.0% | 30.0% | 18.0% | 20.0% | 38.3% | 23.0% | 28.0% | 23.0% | 9.0% | 96.0% |
| Persian| 38.9% | 15.0% | 8.0% | 13.0% | 38.0% | 9.0% | 4.0% | 7.0% | 25.0% | 15.0% | 29.0% | 47.0% | 22.0% | 23.0% | 22.0% | 16.0% | 99.0% |
| PGI*   | 36.7% | 5.0% | 1.0% | 14.0% | 42.0% | 2.0% | 10.0% | 1.0% | 15.0% | 21.0% | 16.0% | 45.0% | 22.0% | 27.0% | 23.0% | 13.0% | 95.0% |
| Turkmen| 36.7% | 3.0% | 1.0% | 18.0% | 39.1% | 6.0% | 0.0% | 5.0% | 20.0% | 20.0% | 2.0% | 47.0% | 12.1% | 23.0% | 28.0% | 10.0% | 97.0% |

* Persian Gulf Islander.
Table 6. The frequency of CYP450s homozygous and heterozygous genotypes based on the most frequent SNPs in the Iranian population.

| Genotype    | Allele   | Homozygous | Heterozygous |
|-------------|----------|------------|--------------|
| CYP1A2*1F   | 41.5%    | 36.6%      |
| CYP2B6*2    | 0.5%     | 9.6%       |
| CYP2B6*3    | 0.0%     | 2.6%       |
| CYP2B6*5    | 0.6%     | 15.7%      |
| CYP2B6*9    | 6.2%     | 40.6%      |
| CYP2B6*22   | 0.0%     | 5.2%       |
| CYP2C8*2    | 0.2%     | 4.2%       |
| CYP2C8*4    | 0.1%     | 5.1%       |
| CYP2C9*2    | 0.7%     | 19.5%      |
| CYP2C9*3    | 1.7%     | 17.0%      |
| CYP2C19*2   | 0.7%     | 19.5%      |
| CYP2D6*2    | 24.4%    | 45.3%      |
| CYP2D6*4    | 1.7%     | 19.0%      |
| CYP2D6*10   | 3.1%     | 24.0%      |
| CYP2D6*41   | 3.1%     | 21.7%      |
| CYP2E1*4    | 0.3%     | 10.7%      |
| CYP3A5*3    | 93.9%    | 5.8%       |

In this regard, *common alleles* were defined as having minor allele frequency (MAF) > 1%. In contrast, rare variants or alleles had an allelic frequency ranging from 0.1% to 1%, and those with a frequency less than 0.1% were considered zero.

3. Results and Discussion

Several studies have reported the frequency of different CYP alleles in selected populations of Iranian healthy volunteers or patients [56–58]. However, most researchers have concentrated on a specific group of single nucleotide variants (SNVs) in each gene and studied the frequency of the alleles in a small group of mentioned populations [59–62]. In addition, relying on the findings of these studies can be problematic due to the disparities in genotyping methods and designed assay panels [11,63–65].

Recently, a comprehensive review was performed on 173 SNPs in the Iranian population. Using the Iranome website, https://gnomad.broadinstitute.org, accessed on 10 August 2022, and a literature review [37], the prevalence of the most frequent alleles was compared to the world’s five significant populations and the Caucasian race. Given all of the preceding, the Iranome database consisting of a whole exome sequencing of 800 individuals from Iran’s eight major ethnic groups (Arab, Azeri, Baloch, Kurd, Lur, Persian, Persian Gulf Islander, and Turkmen) was considered the primary source of data in this review. These data allow an accurate analysis of the genetic polymorphisms of the necessary CYP450 enzymes across Iranian ethnicities. In the next step, extracted data were compared to the Caucasian race and European and Middle Eastern populations using a literature review and other available databases.

In this regard, 17 SNPs associated with nine important CYP450 isoenzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5) were analyzed and will be discussed in greater detail.

3.1. CYP1A2

A previous study demonstrated that the frequency of the *1 allele in the Iranian population was 39.8% [37]. The only SNP with a frequency greater than 1% in the Iranian population is the *1F allele, which has a frequency of 59.9%. The Persian (66.8%) and the Persian Gulf Islander (50%), among the eight Iranian ethnicities, have the highest and lowest frequency, respectively (Table 2 and Figure 1).
Figure 1. Comparison of most frequent SNPs in 8 major Iranian ethnicities and mean frequency in the Iranian population.

There are no similarities in the frequency of the *1F allele between Iranian ethnicities and any other studied populations (Caucasian, European, Middle Eastern) (difference more significant than 1%) (Tables 3 and 4) [44,47,55]. Additionally, genotypic analysis of these
ethnicities revealed that the Kurds (51.5%) and the Persian Gulf Islanders (31.6%) have the highest and lowest frequency of homozygote genotype of CYP1A2*1F, respectively. In comparison, the Baloch (42.4%) and Kurds (28.8%) had the highest and lowest heterozygote genotype frequencies, respectively (Table 5 and Figure 2). In the Iranian population, the mean frequency of CYP1A2 homozygous and heterozygous genotypes based on the *1F allele were 41.5% and 36.6%, respectively (Table 6 and Figure 2).

![Figure 2](image-url)  
**Figure 2.** Comparison of CYP450s homozygous and heterozygous genotypes based on most frequent SNPs in major Iranian ethnicities and mean frequency in the Iranian population.
3.2. CYP2B6

The *1 allele was found in 54.7% of the Iranian population [37]. The *9 allele had the highest prevalence (26.6%) in the Iranian population, ranging from 30.5% in the Lur to 24.0% in the Persian (Table 2, Figure 1). The frequency of this allele among the Iranian Arabs was similar to the Caucasian race [66], the Persian similar to the European population (Table 3), and the Lur to the Middle Eastern population (Table 4) [40,45,52]. Additionally, genotypic investigation of these ethnicities revealed that the Lur (9%) and Persian (5%) had the highest and lowest frequency of homozygote genotypes, respectively. In comparison, the Lur (43%) and the Persian (38%), respectively, had the highest and lowest frequency of heterozygote genotypes (Table 5 and Figure 2). In the Iranian population, the mean frequency of CYP2B6 homozygous and heterozygous genotypes based on the *9 allele were 6.2% and 40.6% (Table 6 and Figure 2).

The *5 allele was the second most prevalent allele (8.5%) among the Iranian population, ranging from 10% in the Arab and Baloch to 6.5% in the Persian (Table 2 and Figure 1). This allele frequency among Arab and Baloch of the Iranian population was similar to the Caucasian race [66]. In contrast, none of the Iranian ethnicities were similar to the European population (Table 3) or the Middle Eastern population (Table 4) [40,45,52]. Furthermore, genotypic analysis of these ethnicities revealed that the Baloch (2%) had the highest frequency of homozygote genotype, while Turkmen, Lur, Far, and Persian Gulf Islander did not. On the other hand, among the Iranian population, Arab and Turkmen (18%) and Persian (13%) had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 2). The mean frequency of CYP2B6 homozygous and heterozygous genotypes based on the *5 allele were 0.6% and 15.7% in the Iranian population, respectively (Table 6 and Figure 2).

Among Iranian ethnics, the *2 allele prevalence ranged from 8.5% in the Persian to 1.5% in the Turkmen (Table 2 and Figure 1). The frequency of the *2 allele among Baloch and Lur of the Iranian populations was similar to the Caucasian race [66]. In contrast, none of the Iranian ethnicities were similar to the European population (Table 3) or the Middle Eastern population (Table 4) [40,45,52]. Additionally, a genotypic investigation of Iranian ethnics revealed that the homozygote genotype was not found among any of the Iranian ethnicities. On the other hand, among the Iranian population, the Persian (8%) had the highest frequency of heterozygote genotype. In comparison, the Baloch showed no heterozygote genotype (Table 5 and Figure 2). In the Iranian population, the mean frequency of CYP2B6 homozygous and heterozygous genotypes based on the *2 allele was 0.5% and 9.6% in the Iranian population (Table 6 and Figure 2).

The *22 allele had a 2.6% frequency in the Iranian population. It ranged from 4.5% among the Persians to 1% among the Persian Gulf Islanders (Table 2 and Figure 1). This allele’s frequency was similar to that of the Caucasian race, except for Persian and Persian Gulf Islanders [67]. Moreover, the frequency of this allele was similar to the European population of Kurd, Lur, and Persian Gulf Islanders (Table 3). Furthermore, a genotypic investigation of these ethnicities revealed that the homozygote genotype was not found among any of the Iranian ethnicities. The Persian (95) and the Persian Gulf Islander (2%), on the other hand, had the highest and lowest frequency of heterozygote genotype among the Iranian population, respectively (Table 5 and Figure 2). In the Iranian population, the mean frequency of CYP2B6 homozygous and heterozygous genotypes based on the *22 allele was 0 and 5.2%, respectively (Table 6 and Figure 2).

The *3 allele had the lowest prevalence (1.3%) in the Iranian population, ranging from 4% in the Persians to 0% in the Baloch (Table 2 and Figure 1). The frequency of this allele in the Azeri, Persian Gulf Islander, and Turkmen populations was similar to that of the Caucasian race and the European population (Table 3) [66]. Similar to the *22 allele, genotypic analysis of these ethnicities revealed that the homozygote genotype was not found among any Iranian ethnicity. On the other hand, the Persian race (8%) had the highest frequency of heterozygote genotype. In comparison, the Baloch showed no heterozygote genotype (Table 5 and Figure 2). In the Iranian population, the mean
frequency of CYP2B6 homozygous and heterozygous genotypes based on the *3 allele was 0 and 2.6%, respectively (Table 6 and Figure 2).

3.3. CYP2C8

According to the previous study, the frequency of the *1 allele was 95% in the Iranian population [37]. The *4 allele prevalence ranged from 5.5% in the Kurds to 0.5% in the Persians among Iranian ethnicities (Table 2 and Figure 1). None of the Iranian ethnicities had a frequency of the *4 allele similar to the Caucasian race [68]. The frequency of this allele among the Kurds was similar to the European population (Table 3). Moreover, Arab, Lur, and Turkmen populations were similar to the Middle Eastern population regarding the *4 allele frequency (Table 4) [50]. Additionally, a genotypic study of Iranian ethnicities revealed that only the Azeri race had a 1% frequency of homozygote genotype, whereas the homozygote genotype was not found in other ethnicities. On the other hand, the Kurds (11%) and the Persian Gulf Islanders (1%) had the highest and lowest frequency of heterozygote genotype among the Iranian population, respectively (Table 5 and Figure 3).

In the Iranian population, the mean frequency of CYP2C8 homozygous and heterozygous genotypes based on the *4 allele was 0.1% and 5.1%, respectively (Table 6 and Figure 3).

The prevalence of the *2 allele ranged from 6% in the Persian Gulf Islanders to 0% in Turkmen (Table 2 and Figure 1). The frequency of the *2 allele among the Lur was similar to the Caucasian race and the European population (Table 3) [54]. Additionally, a genotypic study of Iranian ethnicities revealed that only Persian Gulf Islanders and Baloch had a 1% frequency of the homozygote genotype. Other ethnicities, on the other hand, did not have the homozygote genotype. In the Iranian population, the Persian Gulf Islanders (10%) had the highest frequency of heterozygote genotype. In comparison, the Turkmen lacked the heterozygote genotype (Table 5 and Figure 3). In the Iranian population, the mean frequency of CYP2C8 homozygous and heterozygous genotypes based on the *2 allele was 0.2% and 4.2%, respectively (Table 6 and Figure 3).

3.4. CYP2C9

According to our previous study [37], the *1 allele had a 78.1% prevalence. Among Iranian ethnicities, the *2 allele prevalence ranged from 15% in Lur to 7% in Arab (Table 2 and Figure 1). None of the Iranian ethnicities had the same frequency of the *2 allele as the Caucasian race. However, the frequency of this allele among Azeris was similar to the European population (Table 3) [55]. Moreover, regarding *2 allele frequency, the Azeri and Turkmen were similar to the Middle Eastern population (Table 4) [40,41,43,46]. Additionally, a genotypic study of Iranian ethnicities revealed that Persian and Persian Gulf Islanders had the highest homozygote genotype (2%), while Lur, Turkmen, Kur, and Baloch did not. However, among the Iranian population, the Lur (30%) and Arab (12%) had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 3).

In the Iranian population, the mean frequency of CYP2C9 homozygous and heterozygous genotypes based on the *2 allele was 0.7% and 19.5% (Table 6 and Figure 3).

Among Iranian ethnicities, the *3 allele prevalence ranged from 14.5% in Baloch to 7% in Arabs (Table 2 and Figure 1). None of the Iranian ethnicities had a frequency of the *3 allele similar to the Caucasian race. However, the frequency of this allele among the Azeri and Arab populations was similar to the European population (Table 3) [55]. Moreover, except for Baloch and Persian Gulf Islanders, all Iranian ethnicities were similar to the Middle Eastern population in terms of the *3 allele frequency (Table 4) [40,41,43,46]. Additionally, a genotypic study of Iranian ethnicities revealed that Baloch had the highest frequency of homozygote genotype (5%), while Arab and Azeri did not. On the other hand, the Persian Gulf Islanders (21%) and Arab and Kurds (14%) had the highest and lowest frequency of heterozygote genotype among the Iranian population, respectively (Table 5 and Figure 3). In the Iranian population, the mean frequency of CYP2C9 homozygous and heterozygous genotypes based on the *3 allele was 1.7% and 17%, respectively (Table 6 and Figure 3).
Figure 3. Comparison of CYP450s homozygous and heterozygous genotypes based on most frequent SNPs in major Iranian ethnicities and mean frequency in the Iranian population.
3.5. CYP2C19

The frequency of the *1 allele in the Iranian population was 85.8% [37]. The only allele with a frequency of more than 1% among the Iranian population was the *2 allele. Its prevalence ranged from 18% in the Baloch to 11% in the Azeri, Lur, Kurd, and Persian Gulf Islanders (Table 2 and Figure 1). The frequency of the *2 allele was similar in the Arabs and Caucasians. However, among the Persian and Turkmen, its frequency was similar to the European population (Table 3) [55]. Moreover, the Baloch was similar to the Middle Eastern population regarding the *2 allele frequency (Table 4) [40,45,46,49]. Additionally, genotypic analysis of these ethnicities revealed that the Baloch (4%) and Fars, Arab, and Lur (2%) had the highest and lowest frequency of homozygote genotypes, respectively (Table 5 and Figure 3). In comparison, the Persian (29%) and Persian Gulf Islander (16%) populations had the highest and lowest frequency of heterozygote genotype, respectively (Table 6 and Figure 3). In the Iranian population, the mean frequency of CYP2C19 homozygous and heterozygous genotypes based on the *2 allele was 2% and 22.3%, respectively (Table 6 and Figure 3).

3.6. CYP2D6

A previous study found that the frequency of the *1 allele in the Iranian population was 10.6% [37]. The prevalence of the *2 allele was the highest in the Iranian population (47%), ranging from 53% in Baloch to 42% in Azeri (Table 2 and Figure 4). The frequency of the *2 allele among all Iranian ethnics was similar to the Caucasian race (Table 3) [55]. However, none were similar to the Middle Eastern population (Table 4) [39,48,51]. Furthermore, a genotypic analysis of these ethnicities revealed that the Baloch (32%) and Azeri (17%) had the highest and lowest frequency of homozygote genotype, respectively. In comparison, the Persian (29%) and Persian Gulf Islander (16%) populations had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 3). In the Iranian population, the mean frequency of CYP2D6 homozygous and heterozygous genotypes based on the *2 allele was 24.4% and 45.3%, respectively (Table 6 and Figure 3).

Figure 4. Comparison of most frequent SNPs in 8 major Iranian ethnicities and mean frequency in the Iranian population.
Figure 5. Comparison of CYP450s homozygous and heterozygous genotypes based on most frequent SNPs in major Iranian ethnicities and mean frequency in the Iranian population.
The *10 allele prevalence ranged from 22.5% in Azeris to 10% in the Arabs (Table 2 and Figure 4). None of the Iranian ethnics had the same frequency of the *10 allele as the Caucasian race, the European population (Table 3) [55] or the Middle Eastern population (Table 4) [39,48,51]. Additionally, genotypic analysis of these ethnics revealed that the Azeri (7%) and Lur, Arab, and Persian Gulf Islander (1%) had the highest and lowest frequency of homozygote genotype, respectively. In comparison, the Azeri (31%) and Baloch (17%) had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 5). In the Iranian population, the mean frequency of CYP2D6 homozygous and heterozygous genotypes based on the *10 allele was 3.1% and 24%, respectively (Table 6 and Figure 5).

The *41 allele prevalence ranged from 18.5% in the Persian to 8.5% in the Persian Gulf Islander (Table 2 and Figure 4). The frequency of the *41 alleles among Turkmen and Persian Gulf Islander was similar to the Caucasian race and Turkmen to the European population (Table 3) [53]. Furthermore, except for Turkmen and Persian Gulf Islanders, the frequency of this allele was comparable to the Middle Eastern population (Table 4) [39,48,51]. Additionally, a genotypic analysis of these ethnics revealed that Azeri, Kurd, Lur, and Baloch (4%) and Arab (1%) had the highest and lowest homozygote genotypes, respectively. In comparison, Azeri (29%) and Baloch (11%) had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 5). In the Iranian population, the mean frequency of CYP2D6 homozygous and heterozygous genotypes based on the *41 allele was 3.1% and 21.7%, respectively (Table 6 and Figure 5).

With a prevalence of more than 1%, the *4 alleles had the lowest frequency among CYP2D6 alleles (Table 2 and Figure 4). None of the Iranian ethnics had the same frequency of the *4 allele as the European population (Table 3) [55]. However, the frequency of this allele among Kurds and Turkmen was similar to the Middle Eastern population (Table 4) [39,48,51]. Additionally, a genotypic analysis of these ethnics revealed that Azeri, Kurd, Lur, and Baloch (4%) and Arab (1%) had the highest and lowest homozygote genotypes, respectively. In comparison, Azeri (29%) and Baloch (11%) had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 5). In the Iranian population, the mean frequency of CYP2D6 homozygous and heterozygous genotypes based on the *4 allele was 1.7% and 19%, respectively (Table 6 and Figure 5).

3.7. CYP2E1

The *1 allele frequency in the Iranian population was 94.1% [37]. The *4 allele, with a 5.6% frequency in the Iranian population, is the only one with a frequency of more than 1%. (Table 2, Figure 4). None of the Iranian ethnics had the same frequency of the *4 allele as the European population (Table 3) [55]. At the same time, the Azeri was similar to the Middle Eastern population regarding the *4 allele frequency (Table 4) [46]. The Persian (8%) and the Azeri (3.5%) also had this allele’s highest and lowest frequency, respectively. The homozygote genotype was found only in Kurds and Lurs (1%), with no other ethnics having this allele. In addition, the Persian (16%) and the Azeri (7%) had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 5). In the Iranian population, the mean frequency of CYP2E1 homozygous and heterozygous genotypes based on the *4 allele was 0.3% and 10.7%, respectively (Table 6 and Figure 5).

3.8. CYP3A4

In the Iranian population, the prevalence of the *1 allele was 99.7% [37]. The frequency of mutated alleles of the CYP3A4 enzyme was less than 0.5% among the Iranian population (Table 2).

3.9. CYP3A5

According to our previous research, the prevalence of the *1 allele in the Iranian population was 3.8% [37]. The *3 allele, with a 96.1% frequency in the Iranian population,
was the only one with a frequency of more than 1%. (Table 2 and Figure 4). The frequency of the *3 allele among all Iranian ethnicities, except Persian, Turkmen, and Lur, was similar to the Caucasian race [55] while showing no similarity with the European (Table 3) or Middle Eastern populations (Table 4) [38,42]. The Persian (98.2%) and the Arab (94.8%) had this allele’s highest and lowest frequencies, respectively. Genotypic analysis of these ethnicities revealed that the Persian (99%) and Arab (88%) had the highest and lowest frequency of homozygote genotypes, respectively. In comparison, the Arab (11%) and Persian (0%) had the highest and lowest frequency of heterozygote genotype, respectively (Table 5 and Figure 5). In the Iranian population, the mean frequency of CYP3A5 homozygous and heterozygous genotypes based on the *3 allele was 93.9% and 5.8%, respectively (Table 6 and Figure 5).

The current and previous studies on eight major Iranian ethnicities found that Iranian ethnicities should be considered individually and personalized in personalized medicine. Moreover, the genetic metabolism of the Iranian population and its races may not be conducted based on previous research on other races or populations around the world. Further, remarkable variations are observed among Iranian ethnicities. Thus, studies on one or a few races do not accurately represent the Iranian population. Finally, we hope that more accurate studies on the genetic and phenotypic status of Iranian cities and people, precisely the physiologic and pathophysiologic information of the medical sciences on the metabolism and other processes in the human body, will be revealed, leading to personalized medicine based on the specific status of the individual to improve the efficacy and reduce the side effects and treatment costs.

4. Conclusions

A comparison of the most common SNPs in the Iranian population in eight major Iranian ethnicities revealed significant differences between these ethnicities. Although many previous studies on the polymorphisms of major CYP isoforms in the Iranian population were based on the population’s proximity to the Caucasians, the findings of this study indicate significant genetic differences among eight major Iranian ethnicities and with the Caucasian race, and European and Middle Eastern populations. In addition, there was variation in eight significant ethnicities of the Iranian population regarding the allele frequency and genotype of CYP450s. As a result, it can be concluded that Iranian ethnicities should be treated as a distinct population in future genotypic and phenotypic studies of CYP enzyme activity compared to other populations. Moreover, it should be noted that each ethnicity of the Iranian population has its own set of SNP frequency and genotypes. More ethnicity-specific data can help build a complete picture of genetic variations, resulting in more accurate dose adjustments in patients and, thus, faster progress in personalized medicine. Finally, it appears that we need to go a step further and analyze each individual to determine the exact genotype of a patient to select the best medical option and action for that individual. Besides studying the activity of CYP450 enzymes, it is crucial to study the phenotype of these enzymes and their genotype. Numerous studies have shown that, despite the normal genetic status of these enzymes in individuals, phenotypes and activities of these enzymes change due to environmental factors such as disease, diet, behavioral habits, and specific lifestyles. Hence, it appears inevitable that these enzymes’ genotype and phenotype correlation be studied simultaneously for greater confidence when analyzing CYP450 enzymes and higher accuracy in personalized medicine studies.

Author Contributions: Conceptualization and methodology, N.N., M.R., Y.H.A. and Y.D.; software, H.G.; data curation, writing—original draft preparation, and writing—review and editing, N.N.; visualization, H.G.; supervision, project administration, and funding acquisition, M.R., Y.H.A. and Y.D. All authors have read and agreed to the published version of the manuscript.

Funding: This work was fully supported by a grant from the National Institute for Medical Research Development of Iran (NIMAD) (grant no. 973068). The funding organization(s) played no role in the
study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Akhoon, N. Precision Medicine: A New Paradigm in Therapeutics. *Int. J. Prev. Med.* 2021, 12, 12. [CrossRef] [PubMed]

2. Mathur, S.; Sutton, J. Personalized medicine could transform healthcare. *Biomed. Rep.* 2017, 7, 3–5. [CrossRef]

3. Goetz, L.H.; Schork, N.J. Personalized medicine: Motivation, challenges, and progress. *Fertil. Steril.* 2018, 109, 952–963. [CrossRef] [PubMed]

4. Samer, C.F.; Lorenzini, K.I.; Rollason, V.; Daali, Y.; Desmeules, J.A. Applications of CYP450 testing in the clinical setting. *Mol. Diagn. Ther.* 2013, 17, 165–184. [CrossRef] [PubMed]

5. Ginsburg, G.S.; Phillips, K.A. Precision Medicine: From Science to Value. *Health Aff.* 2018, 37, 694–701. [CrossRef]

6. Ganoci, L.; Bozina, T.; Mirosevic Skvrce, N.; Lovric, M.; Mas, P.; Bozina, N. Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. *Drug Metab. Pers. Ther.* 2017, 32, 11–21. [CrossRef]

7. Sissao, R.; D'Cotta, H.; Baroiller, J.F.; Toguyeni, A. Mismatches between the genetic and phenotypic sex in the wild Kou population of Nile tilapia *Oreochromis niloticus*. *Peel* 2019, 7, e7709. [CrossRef]

8. Chen, Q.; Zhang, T.; Wang, J.F.; Wei, D.Q. Advances in human cytochrome p450 and personalized medicine. *Curr. Drug Metab.* 2011, 12, 436–444. [CrossRef] [PubMed]

9. Neyshaburinezhad, N.; Rouini, M.; Shirzad, N.; Esteghamati, A.; Nakhjavani, M.; Namazi, S.; Ardakani, Y.H. Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome P450 2C19 gene in six major ethnicities of Pakistan. *Bioengineered* 2021, 12, 4442–4451. [CrossRef]

10. Korytina, G.; Kochetova, O.; Akhmadishina, L.; Viktorova, E.; Victorova, T. Polymorphisms of cytochrome p450 genes in three ethnic groups from Russia. *Balkan Med. J.* 2012, 29, 252–260. [CrossRef]

11. Tabari, M.G.; Naseri, F.; Ataby, M.A.; Marjani, A. Genetic Polymorphism of Cytochrome p450 (2C9) Enzyme in Iranian Baluch Ethnic Group. *Open Biochem. J.* 2015, 9, 37–41. [CrossRef] [PubMed]

12. Nassar, S.F.; Raddassi, K.; Ubhi, B.; Doktorski, J.; Abulaban, A. Precision Medicine: Steps along the Road to Combat Human Cancer. *Cells* 2020, 9, 2056. [CrossRef] [PubMed]

13. Cooper, D.N.; Krawczak, M.; Polychronakos, C.; Tyler-Smith, C.; Kehrer-Sawatzki, H. Where genotype is not predictive of phenotype: Towards an understanding of the molecular basis of reduced penetrance in human inherited disease. *Hum. Genet.* 2013, 132, 1077–1130. [CrossRef] [PubMed]

14. Ieiri, I.; Yamada, S.; Seto, K.; Morita, T.; Kaneda, T.; Mamiya, K.; Tashiro, N.; Higuchi, S.; Otsubo, K. A CYP2D6 phenotype-genotype mismatch in Japanese psychiatric patients. *Pharmacopsychiatry* 2003, 36, 192–196. [CrossRef] [PubMed]

15. Sissao, R.; D'Cotta, H.; Baroiller, J.F.; Toguyeni, A. Mismatches between the genetic and phenotypic sex in the wild Kou population of Nile tilapia *Oreochromis niloticus*. *Peel* 2019, 7, e7709. [CrossRef]

16. Chen, Q.; Zhang, T.; Wang, J.F.; Wei, D.Q. Advances in human cytochrome p450 and personalized medicine. *Curr. Drug Metab.* 2011, 12, 436–444. [CrossRef] [PubMed]

17. Nebert, D.W.; Russell, D.W. Clinical importance of the cytochromes P450. *Lancet* 2013, 382, 165–184. [CrossRef] [PubMed]

18. Neyshaburinezhad, N.; Rouini, M.; Shirzad, N.; Esteghamati, A.; Nakhjavani, M.; Namazi, S.; Ardakani, Y.H. Evaluation of the effect of type 2 diabetes mellitus on CYP450 enzymes and P-gp activities, before and after glycemic control: A protocol for a case-control pharmacokinetic study. *MethodsX* 2020, 7, 100853. [CrossRef]

19. Neyshaburinezhad, N.; Seidabadi, M.; Rouini, M.; Lavasani, H.; Foroumadi, A.; Ardakani, Y.H. Evaluation of hepatic CYP2D1 activity and hepatic clearance in type I and type II diabetic rat models, before and after treatment with insulin and metformin. *Daru* 2020, 28, 479–487. [CrossRef] [PubMed]

20. Neyshaburinezhad, N.; Rouini, M.R.; Entezhari, H.; Lavasani, H.; Ardakani, Y.H. Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model. *Iran. J. Basic Med. Sci.* 2020, 23, 629–635. [PubMed]

21. Neyshaburinezhad, N.; Rouini, M.; Lavasani, H.; Ardakani, Y.H. Evaluation of Cinnamon (Cinnamomum Verum) Effects on Liver Cyp450 2D1 Activity and Hepatic Clearance in Diabetic Rats. *Jundishapur. J. Nat. Pharm. Prod.* 2021, 16, e101797. [CrossRef]
24. Rezai, S.; Neyshaburinezhad, N.; Rouini, M.; Lavasani, H.; Ardakani, Y.H. Can combination therapy with insulin and metformin improve metabolic function of the liver, in type I diabetic patients? An animal model study on CYP2D1 activity. J. Diabetes Metab. Disord. 2020, 19, 2049–2056. [CrossRef]
25. Rouini, M.R.; Ghazi-Khansari, M.; Ardakani, Y.H.; Dasiyan, Z.; Lavasani, H. A disposition kinetic study of tramadol in rat perfused liver. Biopharm. Drug Dispos. 2008, 29, 231–235. [CrossRef]
26. Rollason, V.; Lloret-Linares, C.; Lorenzini, K.I.; Daali, Y.; Gev-Fabry, M.; Piguet, V.; Besson, M.; Samer, C.; Desmeules, J. Evaluation of Phenotypic and Genotypic Variations of Drug Metabolising Enzymes and Transporters in Chronic Pain Patients Facing Adverse Drug Reactions or Non-Response to Analgesics: A Retrospective Study. J. Pers. Med. 2020, 10, 198. [CrossRef]
27. Zanger, U.M.; Schwab, M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharm. Ther. 2013, 138, 103–141. [CrossRef]
28. Lloret-Linares, C.; Rollason, V.; Lorenzini, K.I.; Samer, C.; Daali, Y.; Gev-Fabry, M.; Aubry, J.M.; Desmeules, J.; Besson, M. Screening for genotypic and phenotypic variations in CYP450 activity in patients with therapeutic problems in a psychiatric setting, a retrospective study. Pharm. Res. 2017, 118, 104–110. [CrossRef]
29. Marsoussi, N.; Desmeules, J.A.; Rudaz, S.; Daali, Y. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Biopharm. Drug Dispos. 2018, 39, 3–17. [CrossRef]
30. Tracy, T.S.; Chaudhry, A.S.; Prasad, B.; Thummel, K.E.; Schuetz, E.G.; Zhong, X.B.; Tien, Y.C.; Jeong, H.; Pan, X.; Shireman, L.M.; et al. Interindividual Variability in Cytochrome P450-450-Mediated Drug Metabolism. Drug Metab. Dispos. 2016, 44, 343–351. [CrossRef]
31. Gloor, Y.; Lloret-Linares, C.; Bosilkovska, M.; Perroud, N.; Richard-Lepouriel, H.; Aubry, J.M.; Daali, Y.; Desmeules, J.A.; Besson, M. Genetic Polymorphism of Cytochrome p450 (2C19) Enzyme in Iranian Turkman Ethnic Group. Oman Med. J. 2013, 28, 237–244. [CrossRef]
32. Shah, R.R.; Smith, R.L. Addressing phenoconversion: The Achilles’ heel of personalized medicine. Br. J. Clin. Pharm. 2015, 79, 222–240. [CrossRef]
33. Azarpria, N.; Ashraf, M.J.; Khademi, B.; Darai, M.; Hakimzadeh, A.; Abedi, E. Study the polymorphism of CYP3A5 and CYP3A4 loci in Iranian population with laryngeal squamous cell carcinoma. Mol. Biol. Rep. 2011, 38, 5443–5448. [PubMed] [CrossRef]
34. Hashemi-Soteh, M.B.; Hosseini, E.; Fazelnia, S.; Ghasemian-Sorbeni, F.; Madahian, S.; Shiran, M.R. Frequencies of CYP2B64,5, and 2C9 Variants in a Turkish Population and Functional Relevance for Phenytoin. Genetika 2008, 44, 1133–1136. [CrossRef]
35. Alzahrani, A.M.; Ragia, G.; Hanieh, H.; Manolopoulos, V.G. Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. Biomed. Res. Int. 2013, 2013, 315980. [CrossRef] [PubMed]
36. Al-Mahayri, Z.N.; Patrinos, G.P.; Wattanapokayakit, S.; Iemwimangsa, N.; Fukunaga, K.; Mushiroda, T.; Chantratita, W.; Ali, B.R. Interindividual Variability in Cytochrome P450-450-Mediated Drug Metabolism. Drug Metab. Dispos. 2016, 44, 343–351. [CrossRef]
37. Aynacioglu, A.S.; Brockmoller, J.; Bauer, S.; Sachse, C.; Guelzibey, P.; Ongen, Z.; Nacak, M.; Roots, I. Frequency of cytochrome P450 enzymes in the Arab populations. Br. J. Clin. Pharm. 2020, 104–110. [CrossRef]
38. Aynacioglu, A.S.; Brockmoller, J.; Bauer, S.; Sachse, C.; Guelzibey, P.; Ongen, Z.; Nacak, M.; Roots, I. Frequency of cytochrome P450 enzymes in the Arab populations. Br. J. Clin. Pharm. 2020, 104–110. [CrossRef]
39. Alali, M.; Ismail Al-Khalil, W.; Rijjal, S.; Al-Salhi, L.; Saifo, M.; Youssef, L.A. Frequencies of CYP2D6 genetic polymorphisms in Arab populations. Hum. Genom. 2016, 22, 113202. [CrossRef] [PubMed]
40. Al-Mahayri, Z.N.; Patrinos, G.P.; Wattanapokayakit, S.; Iemwimangsa, N.; Fukunaga, K.; Mushiroda, T.; Chantratita, W.; Ali, B.R. Interindividual Variability in Cytochrome P450-450-Mediated Drug Metabolism. Drug Metab. Dispos. 2016, 44, 343–351. [CrossRef]
41. Alzahrani, A.M.; Ragia, G.; Hanieh, H.; Manolopoulos, V.G. Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. Biomed. Res. Int. 2013, 2013, 315980. [CrossRef] [PubMed]
42. Arıcı, M.; Özhan, G. The evaluation of CYP3A4 and CYP3A5 genetic profiles in Turkish population. J. Fac. Pharm. Istanbul 2016, 46, 15–22. [CrossRef] [PubMed]
43. Aynacioglu, A.S.; Brockmoller, J.; Bauer, S.; Sachse, C.; Guelzibey, P.; Ongen, Z.; Nacak, M.; Roots, I. Frequency of cytochrome P450 variants in a Turkish population and functional relevance for phenytoin. Br. J. Clin. Pharm. 1999, 48, 409–415. [CrossRef] [PubMed]
44. Alzahrani, A.M.; Ragia, G.; Hanieh, H.; Manolopoulos, V.G. Genotyping of CYP2C9 and VKORC1 in the Arabic Population of Al-Ahsa, Saudi Arabia. Biomed. Res. Int. 2013, 2013, 315980. [CrossRef] [PubMed]
45. Bilgen, T.; Tosun, O.; Luleci, G.; Keser, I. Frequencies of four genetic polymorphisms in the CYP1A2 gene in Turkish population. Genetika 2008, 44, 1133–1136. [CrossRef]
46. Ellison, C.A.; Abou El-Ella, S.S.; Tawfik, M.; Lein, P.J.; Olson, J.R. Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers. J. Toxicol. Environ. Health A 2012, 75, 232–241. [CrossRef]
47. Hamdy, S.I.; Hiratsuka, M.; Marmar, N.; Moursi, N.; Ahmed, M.; Mizugaki, M. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br. J. Clin. Pharm. 2002, 53, 596–603. [CrossRef] [PubMed]
48. Khalaj, Z.; Baratieh, Z.; Nikpour, P.; Khanahmad, H.; Mokarian, F.; Salehi, R.; Salehi, M. Distribution of CYP2D6 polymorphism in the Middle Eastern region. J. Res. Med. Sci. 2019, 24, 61. [CrossRef]

49. Sabrli, R.; Kösele, A.; Yilmaz, A.; Doğu Kılıç, I. CYP2C19*1 and CYP2C19*2 Polymorphism in Turkish Patients Being Diagnosed with Stable Coronary Artery Disease and Using Clopidogrel. Bagcilar. Med. Bull. 2021, 6, 53–60. [CrossRef]

50. Sahinogullari, Z.U. Genetic polymorphism of CYP2C8*4 in a healthy Turkish population. Med. Sci. Int. Med. J. 2020, 9, 314–319. [CrossRef]

51. Taskin, B.; Percin, F.E.; Ergun, M.A. Investigation of CYP2D6 Gene Polymorphisms in Turkish Population. Psychopharmacol Bull. 2016, 46, 67–72.

52. Yuce-Artun, N.; Kose, G.; Suzen, H.S. Allele and genotype frequencies of CYP2B6 in a Turkish population. Mol. Biol. Rep. 2014, 41, 3891–3896. [CrossRef]

53. Del Tredici, A.L.; Malhotra, A.; Dedek, M.; Espin, F.; Roach, D.; Zhu, G.D.; Voland, J.; Moreno, T.A. Frequency of CYP2D6 Alleles Including Structural Variants in the United States. Front. Pharm. 2018, 9, 305. [CrossRef]

54. Myrand, S.P.; Sekiguchi, K.; Man, M.Z.; Lin, X.; Tzeng, R.Y.; Teng, C.H.; Hee, B.; Garrett, M.; Kikkawa, H.; Lin, C.Y.; et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: Comparison with Korean, Chinese, and Caucasian populations. Clin. Pharm. Ther. 2008, 84, 347–361. [CrossRef]

55. Namazi, S.; Kojuri, J.; Khalili, A.; Azarpira, N. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. Biochem. Pharm. 2012, 83, 903–908. [CrossRef]

56. Zang, N.; Tajik, N.; Moghaddam, A.S.; Milani, A. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population. Clin. Exp. Pharm. Physiol. 2007, 34, 102–105. [CrossRef]

57. Mahdieh, N.; Rabbani, A.; Firouzi, A.; Zahedmehr, A.; Hoseinimoghaddam, M.; Saedi, S.; Sanati, H.; Basiri, H.; Noohi, F.; Rabbani, B.; et al. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention. Cardiovasc. Toxicol. 2018, 18, 482–491. [CrossRef]

58. Zand, N.; Tajik, N.; Rouini, M.R.; Ghahremani, M.H. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Clin. Exp. Pharm. Physiol. 2012, 39, 3891–3896. [CrossRef]

59. Fricke-Galindo, I.; Cespedes-Garro, C.; Rodrigues-Soares, F.; Naranjo, M.E.; Delgado, A.; de Andres, F.; Lopez-Lopez, M.; Penas-Lledo, E.; Llerena, A. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharm. J. 2016, 16, 113–123. [CrossRef]

60. Gaedigk, A.; Sangkuhl, K.; Whirl-Carrillo, M.; Klein, T.; Leeder, J.S. Prediction of CYP2D6 phenotype from genotype across world populations. Genet. Med. 2017, 19, 69–76. [CrossRef]

61. Kalman, L.V.; Agundez, J.; Appell, M.L.; Black, J.L.; Bell, G.C.; Boukouvala, S.; Bruckner, C.; Bruford, E.; Caudle, K.; Coulthard, S.A.; et al. Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clin. Pharm. Ther. 2016, 99, 172–185. [CrossRef]

62. Adams, I.; Ring, B.J.; Cantrell, V.E.; Jones, D.R.; Eckstein, J.; Ruterbories, K.; Hamman, M.A.; Hall, S.D.; Wrighton, S.A. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos. 2002, 30, 883–891. [CrossRef]

63. Payan, M.; Tajik, N.; Rouini, M.R.; Ghahremani, M.H. Genotype and allele frequency of CYP2C19*17 in a healthy Iranian population. Med. J. Islam. Repub. Iran. 2015, 29, 269.

64. Baghha, F.; Salehi-Far, E.; Janbabai, G.; Zaboli, E.; Hedayatizadeh-Omran, A.; Amjadi, O.; Moradi, S. CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomed. Rep. 2018, 9, 446–452. [CrossRef]

65. Zakeri, S.; Amiri, N.; Pirahmadi, S.; Dinparast Djadid, N. Genetic variability of CYP2B6 polymorphisms in southeast Iranian population: Implications for malaria and HIV/AIDS treatment. Arch. Iran. Med. 2014, 17, 685–691. [CrossRef]

66. Lang, T.; Klein, K.; Fischer, J.; Nussler, A.K.; Neuhaus, P.; Hofmann, U.; Eichelbaum, M.; Schwab, M.; Zanger, U.M. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenomics 2001, 11, 399–415. [CrossRef]

67. Zanger, U.M.; Klein, K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet. 2013, 4, 24. [CrossRef]

68. Bahadur, N.; Leathart, J.B.S.; Mutch, E.; Steimel-Crespi, D.; Dunn, S.A.; Gilissen, R.; Houdt, J.V.; Hendrickx, J.; Mannens, G.; Bohets, H.; et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6-alpha-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 2002, 64, 1579–1589. [CrossRef]